鴻泉物聯(688288.SH):崇福鋭鷹二號減持數過半 累計減持1.05%股份
格隆匯5月31日丨鴻泉物聯(688288.SH)公佈,2021年5月31日,公司收到崇福鋭鷹二號發來的《關於減持杭州鴻泉物聯網技術股份有限公司股份進展情況吿知函》,崇福鋭鷹二號於2021年5月28日至2021年5月31日通過大宗交易方式減持公司無限售流通股合計105萬股,佔公司總股本的1.05%。本次減持計劃數量過半,且減持比例已達到公司總股本的1%,減持計劃尚未實施完畢。
本次權益變動後,崇福鋭鷹二號持有公司無限售流通股數量為379.623萬股,佔公司總股本的比例為3.80%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.